ClinicalTrials.gov
ClinicalTrials.gov Menu

Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01771562
Recruitment Status : Completed
First Posted : January 18, 2013
Last Update Posted : May 20, 2016
Sponsor:
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal. However, the transformation of HIV into a chronic disease needing lifelong antiretroviral treatment (ART) raises new challenges, among others related to a disturbance of glucose metabolism, lipid abnormalities, in addition to the potential effects on children's growth and puberty. Little is known on nutritional and metabolic changes in HIV-infected children on ART in Africa, while implementation of the latest WHO recommendations should eventually lead to an increase in the number of children on ART in this region. Moreover, bio-clinical evolution of untreated children is poorly documented in the African context. It therefore urgently needed to institute a cohort study to evaluate, in the long term, the impact of HIV infection and/or ART on nutritional and metabolic disorders and to characterize the risk factors of their occurrence in children and adolescents infected as they move through adolescent into adulthood.

Condition or disease
HIV-1

Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational [Patient Registry]
Actual Enrollment : 330 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Assessment of Risk Factors of Nutritional and Metabolic Disorders in Children and Adolescent Receiving or Not Antiretroviral Treatment : Growing up With HIV in Senegal
Study Start Date : April 2013
Actual Primary Completion Date : April 2016
Actual Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Prevalence of delayed growth [ Time Frame: Baseline ]
    Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores

  2. Prevalence of delayed puberty [ Time Frame: Baseline ]
    Delayed puberty is assessed by age of entry into puberty and the age of transition to different Tanner staging

  3. Prevalence of lipodystrophy [ Time Frame: Baseline ]
    Lipodystrophy (lipoatrophy, lipohypertrophy, combined forms) is defined by direct observation and by joint analysis of anthropometric measures associated with fat tissue index and lean tissue index measured by electrical bio-impedancemetry

  4. Prevalence of blood lipids ans glucose abnormalities [ Time Frame: Baseline ]
    Measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides

  5. Incidence of delayed growth [ Time Frame: Annually for 3 years from the anniversary date of the study ]
    Delayed growth is defined by height for age < -2 z-scores, wasting (%) by weight-for height < -2 z-scores and/or BMI-age < -2 z-scores

  6. Incidence of delayed puberty [ Time Frame: Annually for 3 years from the anniversary date of the study ]
    Assessed by age of entry into puberty and the age of transition to a different Tanner stage

  7. Incidence of lipodystrophy [ Time Frame: Annually for 3 years from the anniversary date of the study ]
    defined by direct observation and by joint analysis of anthropometric measures associated with changes in fat tissue index and lean tissue index measured by electrical bio-impedancemetry

  8. Incidence of blood lipid and glucose abnormalities [ Time Frame: Annually for 3 years from the anniversary date of the study ]
    Repeated measurement of blood glucose, total cholesterol, HDL, LDL and triglycerides


Biospecimen Retention:   Samples With DNA
Plasma, blood cells and urine samples to be retained

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   2 Years to 15 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV-1 infected individuals age between 2 ans 16 years
Criteria

Inclusion Criteria:

  • HIV-1 infection
  • Age equal or above 2 years and bellow 16 years
  • Follow-up in the participating site
  • Informed consent signed by at least on of the parents or legal guardian who is aware of the child's HIV status

Exclusion Criteria:

  • HIV-2 or HIV-1+2 infection
  • children represented by a legal guardian who is not informed about the child's HIV status
  • Unable to comply with study requirements or procedures according to the investigator's opinion
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01771562


Locations
Senegal
Hôpital d'enfant Albert Royer
Dakar, Senegal
Hôpital Roi Baudoin
Guédiawaye, Senegal
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Investigators
Principal Investigator: Philippe Msellati, MD IRD : French Research Institute for Development
Principal Investigator: Haby Sy Signate, MD Hôpital d'Enfant Albert Royer, Dakar, Senegal
Principal Investigator: Ngagne Mbaye, MD Hôpital Roi Baudoin, Guédiawaye, Senegal
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
Sponsor website  This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier: NCT01771562     History of Changes
Other Study ID Numbers: ANRS 12279 MAGGSEN
First Posted: January 18, 2013    Key Record Dates
Last Update Posted: May 20, 2016
Last Verified: May 2016

Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
HIV-1
Child
Adolescent
Growth
 Lipodystrophy
ARV treatment
Senegal

Additional relevant MeSH terms:
Metabolic Diseases